Home Cart 0 Sign in  

[ CAS No. 93777-26-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 93777-26-5
Chemical Structure| 93777-26-5
Structure of 93777-26-5 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 93777-26-5 ]

Related Doc. of [ 93777-26-5 ]

Alternatived Products of [ 93777-26-5 ]

Product Details of [ 93777-26-5 ]

CAS No. :93777-26-5 MDL No. :MFCD00070755
Formula : C7H4BrFO Boiling Point : -
Linear Structure Formula :- InChI Key :MMFGGDVQLQQQRX-UHFFFAOYSA-N
M.W : 203.01 Pubchem ID :736327
Synonyms :
5-Bromo-2-fluoro-benzaldehyde
Chemical Name :5-Bromo-2-fluorobenzaldehyde

Calculated chemistry of [ 93777-26-5 ]

Physicochemical Properties

Num. heavy atoms : 10
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.0
Num. rotatable bonds : 1
Num. H-bond acceptors : 2.0
Num. H-bond donors : 0.0
Molar Refractivity : 39.49
TPSA : 17.07 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.58 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.82
Log Po/w (XLOGP3) : 2.76
Log Po/w (WLOGP) : 2.82
Log Po/w (MLOGP) : 2.63
Log Po/w (SILICOS-IT) : 3.08
Consensus Log Po/w : 2.62

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.22
Solubility : 0.124 mg/ml ; 0.000609 mol/l
Class : Soluble
Log S (Ali) : -2.77
Solubility : 0.342 mg/ml ; 0.00168 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.48
Solubility : 0.0668 mg/ml ; 0.000329 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.38

Safety of [ 93777-26-5 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 93777-26-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 93777-26-5 ]
  • Downstream synthetic route of [ 93777-26-5 ]

[ 93777-26-5 ] Synthesis Path-Upstream   1~46

  • 1
  • [ 93777-26-5 ]
  • [ 465529-56-0 ]
Reference: [1] Patent: WO2011/18454, 2011, A1,
[2] Patent: WO2011/20861, 2011, A1,
[3] Patent: EP3269715, 2018, A1,
  • 2
  • [ 93777-26-5 ]
  • [ 465529-57-1 ]
Reference: [1] Patent: WO2011/18454, 2011, A1,
[2] Patent: WO2011/20861, 2011, A1,
  • 3
  • [ 93777-26-5 ]
  • [ 51437-00-4 ]
  • [ 53857-57-1 ]
Reference: [1] Journal of Organic Chemistry, 2009, vol. 74, # 16, p. 6331 - 6334
  • 4
  • [ 93777-26-5 ]
  • [ 146137-79-3 ]
YieldReaction ConditionsOperation in experiment
60% Reflux A mixture of 74 (1.82 g, 9 mmol) and copper (I) cyanide (1.4 g, 15.7 mmol) in DMF (14.0 mL) was stirred at reflux overnight. After completion, the reaction mixture was cooled to rt and poured into a solution of water (10 mL) and NH4OH (10 ml) followed by extraction with EtOAc (3 x 25 mL). The organic layer was sequentially washed with brine (2 x 15 mL), dried over anhydrous Na2S04, and concentrated in vacuo to give 757a (0.80 g, 60 percent).
Reference: [1] Journal of Medicinal Chemistry, 2011, vol. 54, # 24, p. 8582 - 8591
[2] Patent: WO2013/56003, 2013, A2, . Location in patent: Page/Page column 63
  • 5
  • [ 93777-26-5 ]
  • [ 146137-79-3 ]
Reference: [1] Patent: US6376499, 2002, B1,
[2] Patent: US6610692, 2003, B1,
  • 6
  • [ 14221-01-3 ]
  • [ 93777-26-5 ]
  • [ 146137-79-3 ]
Reference: [1] Patent: US6384080, 2002, B1,
  • 7
  • [ 544-92-3 ]
  • [ 93777-26-5 ]
  • [ 146137-79-3 ]
Reference: [1] Synthetic Communications, 1997, vol. 27, # 7, p. 1199 - 1207
  • 8
  • [ 93777-26-5 ]
  • [ 146328-85-0 ]
YieldReaction ConditionsOperation in experiment
77%
Stage #1: With sodium hydroxide; dihydrogen peroxide In methanol; water at 20℃; for 2 h;
Stage #2: With hydrogenchloride In methanol; water
Example 103A
5-Bromo-2-fluoro-benzoic Acid
A mixture of 5-bromo-2-fluorobenzaldehyde (810 mg; 4.0 mmol), 15percent NaOH (aq.) (3 mL), MeOH (5 mL), and 30percent H2O2 (5 mL) was stirred at r.t. for 2 hrs., then acidified with 10percent HCl (aq.).
The resulting white solid was collected, rinsed with water, and dried to give the desired product (670 mg; 77percent).
Reference: [1] Bioorganic and Medicinal Chemistry, 2006, vol. 14, # 20, p. 6832 - 6846
[2] Patent: US2003/199511, 2003, A1, . Location in patent: Page/Page column 39
  • 9
  • [ 93777-26-5 ]
  • [ 146328-85-0 ]
YieldReaction ConditionsOperation in experiment
77% With dihydrogen peroxide In methanol Example 103A
5-Bromo-2-fluoro-benzoic Acid
A mixture of 5-bromo-2-fluorobenzaldehyde (810 mg; 4.0 mmol), 15percent NaOH (aq.) (3 mL), MeOH (5 mL), and 30percent H2O2 (5 mL) was stirred at r.t. for 2 hrs., then acidified with 10percent HCl (aq.).
The resulting white solid was collected, rinsed with water, and dried to give the desired product (670 mg; 77percent).
Reference: [1] Patent: US2003/187026, 2003, A1,
  • 10
  • [ 93777-26-5 ]
  • [ 146328-87-2 ]
Reference: [1] Patent: US6384080, 2002, B1,
  • 11
  • [ 93777-26-5 ]
  • [ 99725-13-0 ]
YieldReaction ConditionsOperation in experiment
100%
Stage #1: at 0 - 20℃; for 15 h; Inert atmosphere
Stage #2: With water; ammonium chloride In ethanol at 0℃;
Preparation Example 4(5-Bromo-2-fluorophenyl)methanolTo a solution of 5-bromo-2-fluorobenzaldehyde (30.0 g, 148 mmol) in EtOH was added sodium borohydride (8.39 g, 222 mmol) at 0 °C. The resulting mixture was stirred with gradual warming to ambient temperature over 15 h, re-cooled to 0 °C, and quenched with aq. saturated NH4C1 solution. The mixture was extracted with EtOAc. The organic layer was washed with brine, dried over MgS04, filtered and evaporated in vacuo to yield the titled compound (30.3 g, quantitative) as a white sold, which was carried on to the next step without further purification.[M-OH"]+ 187.
Reference: [1] Patent: WO2011/159067, 2011, A2, . Location in patent: Page/Page column 51
[2] Journal of Medicinal Chemistry, 1999, vol. 42, # 18, p. 3572 - 3587
[3] Patent: US6034093, 2000, A,
[4] Patent: US5731315, 1998, A,
[5] Patent: WO2004/814, 2003, A1, . Location in patent: Page 49
[6] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 13, p. 3934 - 3948
[7] Patent: WO2015/89809, 2015, A1, . Location in patent: Page/Page column 47; 48
[8] Patent: WO2015/95256, 2015, A1, . Location in patent: Page/Page column 48
  • 12
  • [ 67-56-1 ]
  • [ 93777-26-5 ]
  • [ 99725-13-0 ]
YieldReaction ConditionsOperation in experiment
98% at 0 - 20℃; for 0.583333 h; Example 5, Step 1To a solution of starting aldehyde 5-1 (3.98 g, 19.6 mmol) in MeOH (20 mL) at 0°C was added sodium borohydride (1.48 g, 39.2 mmol). The reaction was stirred at 0°C for 5 mm then warmed up to RT and allowed to stir for an additional 30 mm. The final mixture was diluted with EtOAc and brine, and the organic layer was dried over Na2SO4 and concentrated invacuo to provide 3.92 g (9 8percent) of intermediate 5-2.
Reference: [1] Patent: WO2013/142396, 2013, A1, . Location in patent: Page/Page column 51
  • 13
  • [ 446-52-6 ]
  • [ 93777-26-5 ]
YieldReaction ConditionsOperation in experiment
88% With potassium bromate; sulfuric acid In water at 90℃; Example three: equipped with electric stirring, thermometer, Dropping funnel and condenser tube reactor was added 65percent aqueous sulfuric acid 500ml, Potassium bromate 167 g (1 mol), 124.1 g (1 mol) of o-fluorobenzaldehyde was added dropwise thereto, 90 ° C for 2-3 hours, to the system by adding water 1000ml, Extraction with methyl tert-butyl ether, The organic phase was washed with aqueous sodium sulfite, dried over anhydrous sodium sulfate and concentrated by filtration to remove methyl tert-butyl ether to give a brown-red oil. Vacuum distillation collected 63-65 ° C / 3mmHg fraction 178g, Yield 88percent, content 97percent.
Reference: [1] Patent: CN105884591, 2016, A, . Location in patent: Paragraph 0008; 0009; 0010; 0011
  • 14
  • [ 107-31-3 ]
  • [ 460-00-4 ]
  • [ 93777-26-5 ]
YieldReaction ConditionsOperation in experiment
54%
Stage #1: With n-butyllithium; diisopropylamine In tetrahydrofuran; hexane at 78℃; for 2 h;
Stage #2: at -78 - 20℃; for 1.5 h;
To a solution of N,N-diisopropylamine (8.87 mL, 62.9 mmol, 1.1 eq) in dry THF (80 mL) at -78 °C was added n-BuLi (2.5M in hexane, 27.5 mL, 68.5 mmol, 1.2 eq). The resulting mixture was stirred for 30 min then l-bromo-4-fiuoro-benzene (10 g, 57.1 mmol, 1 eq) in dry THF (20 mL) was added. The resultant mixture was stirred at -78 °C for 2h then methyl formate (3.8 g, 62.9 mmol, 1.1 eq) was added and the reaction was stirred a further 30 min at -78 °C. The reaction was allowed to warm to room temperature and stirred a further lh. The reaction was then diluted with water (100 mL), and the aqueous layer was extracted with EtOAc. The combined organic extracts were washed with brine, dried (Na2SC>4), filtered and evaporated in vacuo. The residue obtained was purified by column chromatography (petroleum ethenEtOAc, 20:1) to give the title compound as a yellow oil (6.25 g, 54 percent). 1H NMR (400 MHz, CDCls) δ 10.29 (s, 1H), 7.97 (dd, J = 6.1 , 2.6 Hz, 1H), 7.70 (ddd, J = 8.8, 4.7, 2.6 Hz, 1H), 7.09 (dd, J= 9.6, 8.9 Hz, 1H).
Reference: [1] Patent: WO2013/37705, 2013, A2, . Location in patent: Page/Page column 209; 210
  • 15
  • [ 68-12-2 ]
  • [ 460-00-4 ]
  • [ 93777-26-5 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2004, vol. 14, # 17, p. 4575 - 4579
[2] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 1, p. 279 - 282
  • 16
  • [ 99725-12-9 ]
  • [ 93777-26-5 ]
Reference: [1] Patent: US5489592, 1996, A,
  • 17
  • [ 3132-99-8 ]
  • [ 93777-26-5 ]
Reference: [1] Journal of the American Chemical Society, 2018, vol. 140, # 8, p. 2789 - 2792
  • 18
  • [ 221030-92-8 ]
  • [ 93777-26-5 ]
Reference: [1] Journal of Organic Chemistry, 2018, vol. 83, # 15, p. 7852 - 7859
  • 19
  • [ 93777-26-5 ]
  • [ 74626-47-4 ]
Reference: [1] Synthetic Communications, 1997, vol. 27, # 7, p. 1199 - 1207
  • 20
  • [ 593-85-1 ]
  • [ 93777-26-5 ]
  • [ 190273-89-3 ]
YieldReaction ConditionsOperation in experiment
68% at 140℃; Step 1 : 5-Bromo-2-fluorobenzaldehyde (4.0 g, 19.7 mmol, 1.0 equiv) and guanidine carbonate (2.68 g, 29.7 mmol, 1.51 equiv) were dissolved in DMA (20 mL) and heated to 140°C & stirred for overnight. After completion of starting material, reaction mixture was poured onto ice cold water. The solid was filtered, washed with diethyl ether and dried to get 6-bromoquinazolin-2- amine (3.0 g, 68percent) as off white solid. LCMS (ES) m/z = 234.0, 236.0 [M+H]+. H NMR (400 MHz, DMSO-d6) δ 6.96 (s, 2H), 7.34 (d, J = 8.8 Hz, 1 H), 7.74 - 7.77 (m, 1 H), 8.03 (d, J = 2.0 Hz, 1 H), 9.07 (s, 1 H).
60% at 140℃; for 5 h; 2-Fluoro-5-bromobenzaldehyde (10 g, 49.2 mmol) and bisguanidinium carbonate (13.3 g, 74 mmol) were dissolved in N,N-dimethylacetamide (50 mL). The resulting mixture was heated to reflux and stirred for 5 h. After cooling to room temperature, 120 mL water was added and the reaction mixture was allowed to stir for another 2 h at room temperature. The product was collected by filtration and dried under vacuum to afford 6-bromo-2-quinazolinamine (2) (5.0 g, 60percent).
4 g at 160℃; for 0.5 h; To a solution of 5-bromo-2-fluoro-benzaldehyde (20.0 g, 98.5 mmol) in DMA (700 mL) was added guanidine-carbonic acid (26.6 g, 147.7 mmol). The mixture was stirred at 160°C for 0.5 h, cooled to rt and concentrated. The residue was diluted with H20 (300 mL) and extracted with ethyl acetate (200 mL χ 3). The combined organic layers were washed with brine (100 mL x 3), dried over Na2S04, filtered and concentrated under reduced pressure to give a residue. The residue was washed with DCM (300 mL) to get compound 1A-2 (4.0 g).
Reference: [1] Patent: WO2017/46739, 2017, A1, . Location in patent: Page/Page column 49
[2] European Journal of Medicinal Chemistry, 2017, vol. 141, p. 506 - 518
[3] Journal of Organic Chemistry, 2006, vol. 71, # 10, p. 3959 - 3962
[4] Journal of Medicinal Chemistry, 2006, vol. 49, # 19, p. 5671 - 5686
[5] Journal of Medicinal Chemistry, 2008, vol. 51, # 11, p. 3065 - 3068
[6] Journal of Heterocyclic Chemistry, 1997, vol. 34, # 2, p. 385 - 387
[7] Patent: WO2008/20203, 2008, A1, . Location in patent: Page/Page column 72
[8] Patent: WO2018/102751, 2018, A1, . Location in patent: Paragraph 00208
  • 21
  • [ 93777-26-5 ]
  • [ 190273-89-3 ]
YieldReaction ConditionsOperation in experiment
60% With guanidine carbonate In N,N-dimethyl acetamide at 140℃; for 5 h; Compound 2-Fluoro-5-bromobenzaldehyde (10.0 g, 49.2 mmol)bisguanidiniu carbonate (13.3 g, 74 mmol) were dissolved in N,Ndimethylacetamide(50 mL). The resulting mixture was heated toreflux and stirred for 5 h. After cooling to room temperature,120 mL of water was added and the reaction mixture was allowedto stir for another 2 h at room temperature. The product wascollected by filtration and dried under vacuum to yield 6-Bromo-2-quinazolinamine (12) (5 g, 60percent).
Reference: [1] European Journal of Medicinal Chemistry, 2017, vol. 127, p. 275 - 285
  • 22
  • [ 593-85-1 ]
  • [ 93777-26-5 ]
  • [ 190273-89-3 ]
YieldReaction ConditionsOperation in experiment
73% at 150℃; for 5 h; Guanidine carbonate (2) (4.47 g, 36.9 mmol) was added to a solution of 5-bromo-2-fluorobenzaldehyde (1) (5.00 g, 24.6 mmol) in dimethylacetamide (50 ml). The reaction mixture was heated at 150°C for 5 h. The progress of the reaction was monitored by TLC using AcOEt–hexane, 1:1, as eluent. The reaction mixture was cooled and quenched with ice water, and stirred for 30 min. Then the obtained solid was filtered off, and water was removed by azeotropic distillation with PhMe to get 4.00 g (73percent) of compound 3. Mp 270–272°C. 1H NMR spectrum (300 MHz), δ, ppm (J, Hz): 7.04 (2H, s,NH2); 7.37 (1H, d, J = 9.0, H Ar); 7.78 (1H, dd, J = 9.0,J = 2.4, H Ar); 8.05 (1H, d, J = 2.4, H Ar); 9.09 (1H, s,H Ar). Mass spectrum, m/z: 225 [M+H]+.
Reference: [1] Chemistry of Heterocyclic Compounds, 2015, vol. 51, # 1, p. 60 - 66[2] Khim. Geterotsikl. Soedin., 2015, vol. 51, # 1, p. 60 - 66,7
[3] Journal of Medicinal Chemistry, 2013, vol. 56, # 5, p. 1996 - 2015
  • 23
  • [ 124-46-9 ]
  • [ 93777-26-5 ]
  • [ 190273-89-3 ]
Reference: [1] Patent: US2006/35897, 2006, A1, . Location in patent: Page/Page column 32
[2] Patent: WO2008/68507, 2008, A2, . Location in patent: Page/Page column 47
[3] Patent: WO2006/52555, 2006, A2, . Location in patent: Page/Page column 32; 73
  • 24
  • [ 93777-26-5 ]
  • [ 57639-16-4 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2006, vol. 14, # 20, p. 6832 - 6846
[2] Patent: US2007/37974, 2007, A1,
  • 25
  • [ 93777-26-5 ]
  • [ 446-52-6 ]
  • [ 374538-01-9 ]
Reference: [1] Tetrahedron, 2002, vol. 58, # 9, p. 1657 - 1666
  • 26
  • [ 93777-26-5 ]
  • [ 459133-66-5 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2015, vol. 25, # 19, p. 4143 - 4147
  • 27
  • [ 110-85-0 ]
  • [ 24424-99-5 ]
  • [ 93777-26-5 ]
  • [ 628326-05-6 ]
Reference: [1] Patent: US2013/210798, 2013, A1, . Location in patent: Paragraph 0255; 0256
  • 28
  • [ 93777-26-5 ]
  • [ 57260-71-6 ]
  • [ 628326-05-6 ]
Reference: [1] Journal of Medicinal Chemistry, 2005, vol. 48, # 7, p. 2667 - 2677
[2] Synthesis, 2010, # 24, p. 4287 - 4299
  • 29
  • [ 93777-26-5 ]
  • [ 79762-54-2 ]
YieldReaction ConditionsOperation in experiment
76% With hydrazine hydrate In dimethyl sulfoxide at 120℃; for 21 h; To a vigorously stirred solution of 5-bromo-2-fluorobenzaldehyde (40.6 g, 0.2 mol) in DMSO (80 mL) was added N2H4-xH2O (40 mL, 0.8 mol) dropwise over 15 min (slow addition to keep the reaction not too hot). The resulting yellow slurry was heated at 120 0C (oil temp.) for 21 h. The whole mixture was transferred to a 1 L flask and cooled for 10 min in air before quenching with ice (300 mL) and ice- cold H2O (100 mL). The resulting mixture was stirred for 30 min at it. Precipitated formed was collected by suction filtration, rinsed thoroughly with H2O (100 mL x 2), 2 M HCl (100 mL x 2), H2O (100 mL x 2), 0.5 M Na2CO3 (100 mL x 2), H2O (100 mL x 2), dried in air for 1 h and under high vacuum for 2 days to give 6- bromo-lH-indazole (30.05 g, 76percent) as a light yellow solid. MS ESI 196.9 [M + H]+, calcd for [C7H5BrN2 + H]+ 197.0.
Reference: [1] Patent: WO2009/79767, 2009, A1, . Location in patent: Page/Page column 84
  • 30
  • [ 93777-26-5 ]
  • [ 552331-16-5 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2006, vol. 14, # 20, p. 6832 - 6846
[2] Journal of Medicinal Chemistry, 2012, vol. 55, # 2, p. 935 - 942
[3] Journal of Medicinal Chemistry, 2017, vol. 60, # 14, p. 6018 - 6035
[4] Patent: WO2007/126964, 2007, A2,
  • 31
  • [ 75-16-1 ]
  • [ 93777-26-5 ]
  • [ 552331-15-4 ]
YieldReaction ConditionsOperation in experiment
100%
Stage #1: at 0℃; for 0.5 h;
Stage #2: With hydrogenchloride; water In tetrahydrofuran; diethyl ether; toluene
J. 1-(5-bromo-2-fluorophenyl)ethan-1-ol. To a solution of 5-Bromo-2-fluorobenzaldehyde (10.0 g., 49.26 mmol) in anhydrous ether (60 mL) at 0° C. was added 1.4M methyl magnesium bromide (THF/Tol. solution) (36.9 mL) dropwise. The solution stirred for 30 minutes and quenched with water (50 mL) followed by 1N HCl (10 mL). The organics were separated and dried over magnesium sulfate, filtered and solvent removed under reduced pressure to afford the title compound (10.8 g., 100percent). MS (ESI) m/z 218 [M+1]+, 220 [M+2]+.
93%
Stage #1: for 1 h;
[00199] 5-Bromo-2-fluro-phenyl-methanol: 5-Bromo-2-fluorobenzaldehyde(commercially available from Aldrich)( 150.0 g, 739 mmol) was charged into a 2 liter round bottom flask. The reaction mixture in the flask was immersed in an ice-water bath. Methylmagnesium bromide (270 mL, 812 mmol) was added dropwise via an addition funnel. The reaction mixture was stirred for one hour following completion of the addition. After the reaction was completed, the mixture was slowly poured into 500 mL ice water and 250 mL saturated ammonium chloride. The resulting aqueous solution was extracted with ether (800 mL x2) in a separation funnel. The combined ether layer was washed with brine and dried over sodium sulfate. Removal of the solvent gave the product (150 g, yield = 93percent). The product was used directly in the next step without further purification.
93% at 0℃; for 1 h; Commercially available 4a (150.0 g,</p> <p id="p0144" num="0144">739 mmol) was charged into a 2 liter round bottom flask. The reaction mixture in the flask was immersed in an ice-water bath. Methylmagnesium bromide (270 ml, 812 mmol) was added dropwise via an additional funnel. The reaction mixture was continually stirred for one more hour after the addition. After the reaction was completed, the mixture was slowly poured into 500 ml ice water plus 250 ml saturated ammonium chloride. The resulting aqueous solution was extracted with ether (800 ml x2) in a separation funnel. The combined ether layer was washed with brine and dried over sodium sulfate. Removal of the solvent gave the product (4b) (150 g, yield = 93percent). The product was used directly for the next step without further purification.
53%
Stage #1: at 0 - 20℃; for 14.5 h;
Stage #2: With water In tetrahydrofuran
Methylmagnesium bromide (3M solution in tetrahydrofuran, 18 ml, 54.2 mmol) was added to a solution of 5-bromo-2-fluorobenzaldehyde (10.0 g, 49.3 mmol) under nitrogen at 0° C. over 30 min. The resulting solution was allowed to warm to room temperature over 14 h, upon which TLC analysis showed no remaining starting material, and two new products. The mixture was quenched with water, diluted with ethyl acetate and the organic phase removed and dried over sodium sulfate. This was then concentrated and purified by column chromatography (120 g ISCO column eluting with hexanes and ethyl acetate; gradient 100percent hexanes to 50percent hexanes). The second fraction was collected as the product, providing the alcohol (5.8 g, 53percent) as an oil; 1H NMR (500 MHz, CDCl3) δ 7.65-7.63 (dd, J=6.5, 2.6 Hz, 1H), 7.36-7.33 (ddd, J=8.7, 4.6, 2.6 Hz, 1H), 6.93-6.89 (dd, J=9.9, 8.7 Hz, 1H), 5.17-5.16 (m, 1H), 1.91-1.90 (m, 1H), 1.51-1.49 (d, J=6.4 Hz, 3H).
46 g at 0℃; for 0.5 h; A solution of 5-bromo-2-fluoro-benzaldehyde (55.0 g, 270.9 mmol) in THF (500.0 mL) was cooled to 0°C. Then MeMgBr (3 M, 94.8 mL) was added. The mixture was stirred at 0°C for 0.5 h, quenched with H4C1 (500 mL) and extracted with ethyl acetate (500 mL χ 3). The combined organic layers were washed with brine (500 mL χ 3), dried over Na2S04, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (Si02) to afford compound 31-2 (46.0 g).

Reference: [1] Patent: US2008/242694, 2008, A1, . Location in patent: Page/Page column 41
[2] Bioorganic and Medicinal Chemistry, 2006, vol. 14, # 20, p. 6832 - 6846
[3] Patent: WO2009/11880, 2009, A2, . Location in patent: Page/Page column 95
[4] Patent: WO2006/44860, 2006, A2, . Location in patent: Page/Page column 23
[5] Patent: US2006/142307, 2006, A1, . Location in patent: Page/Page column 24
[6] Patent: WO2006/81230, 2006, A2, . Location in patent: Page/Page column 68-69
[7] Patent: US2003/199511, 2003, A1, . Location in patent: Page/Page column 38
[8] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 5, p. 1652 - 1656
[9] Journal of Medicinal Chemistry, 2017, vol. 60, # 14, p. 6018 - 6035
[10] Patent: WO2018/102751, 2018, A1, . Location in patent: Paragraph 00260
[11] Patent: WO2007/126964, 2007, A2, . Location in patent: Page/Page column 89
  • 32
  • [ 676-58-4 ]
  • [ 93777-26-5 ]
  • [ 552331-15-4 ]
YieldReaction ConditionsOperation in experiment
37%
Stage #1: at 0℃;
Stage #2: With water; ammonium chloride In tetrahydrofuran
Acid Preparation 5; 3-Methyl-1 H-indazole-5-carboxvlic acid; To a cooled solution of 3-bromobenzaldehyde (42.5 g, 209 mmol) in THF (300 ml_) at 0 aC was added MeMgCI (17.2 g, 230 mmol) and the mixture was stirred for 2 hours. The reaction mixture was quenched with saturated NH4CI solution (100 ml_) and extracted with diethyl ether (2x250 ml_). The combined organic layers were washed with water (2x100 mL), saturated aqueous NaCI (100 mL), dried over anhydrous Na2SO4 and concentrated to give 1-(5-bromo-2-fluoro-phenyl)-ethanol (17 g, 37percent) as an oil. 1H NMR (CDCI3): δ 7.6-7.7 (d, 1 H), 7.3-7.4 (m, 1 H), 6.8-6.9 (t, 1 H), 5.1-5.2 (m, 1 H), 1.8-1.9 (br, 1 H), 1.46-1.55 (d, 3H).
14.51 g at -78 - -5℃; for 1 h; Inert atmosphere Step 1 [0200] 5-Bromo-2-fluorobenzaldehyde (1) (12.98 g) was dissolved in tetrahydrofuran (60 ml) under nitrogen atmosphere, and the solution was cooled in a dry ice-acetone bath. To the solution was added dropwise methylmagnesium chloride (3M in THF, 25.6 ml) at a temperature between −78° C. and −30° C. After completion of addition, the mixture was stirred at a temperature between −10° C. and −5° C. for 1 hour. To the reaction solution were added an aqueous saturated ammonium chloride solution and water, extracted with ethyl acetate and washed subsequently with water and brine. The organic layer was dried over anhydrous magnesium sulfate and the solvent was evaporated under reduced pressure to afford Compound 2 (14.51 g). [0201] 1H-NMR (CDCl3) δ: 1.50 (d, J=6.4 Hz, 3H), 1.91 (d, J=4.2 Hz, 1H), 5.16 (dq, J=4.2, 6.4 Hz, 1H), 6.91 (dd, J=9.9, 8.7 Hz, 1H), 7.31-7.38 (m, 1H), 7.64 (dd, J=6.5, 2.5 Hz, 1H).
Reference: [1] Patent: WO2009/144554, 2009, A1, . Location in patent: Page/Page column 43
[2] Journal of Medicinal Chemistry, 2012, vol. 55, # 2, p. 935 - 942
[3] Patent: US2013/210839, 2013, A1, . Location in patent: Paragraph 0200; 0201
  • 33
  • [ 75-16-1 ]
  • [ 93777-26-5 ]
  • [ 198477-89-3 ]
YieldReaction ConditionsOperation in experiment
87%
Stage #1: at 0℃; for 0.55 h;
Stage #2: With Jones reagent In diethyl ether; acetone
To a 0° C. stirred solution of 5-bromo-2 fluoro-benzaldehyde (5.00 g, 24.6 mmol) in anhydrous ether (100 mL) under nitrogen gas was added via syringe MeMgBr (3M solution in ether, 10 mL, 30 mmol) over 3 min. After 30 min, TLC showed the reaction completed. The mixture was poured into a saturated solution of sodium bicarbonate (100 mL), the organic layer was separated and the aqueous layer was extracted with ethyl acetate (100 mL). The combined organic layers were dried over magnesium sulfate, filtered, and concentrated to give a viscous oil. The oil was mixed with acetone (100 mL) and treated with Jones reagent (1.1 M, 40 mL, 1.79 mmol). The mixture was stirred overnight, acetone was evaporated and the residue was extracted with ethyl acetate (60 mL.x.2). The extracts were washed with water (50 mL) and then a saturated aqueous solution of sodium bicarbonate (50 mL). Evaporation gave the ketone as an oil (4.63 g, 87percent) that was used in the next reaction without further purification
87% at 0℃; for 0.05 h; To a 0° C. stirred solution of 5-bromo-2 fluoro-benzaldehyde (5.00 g, 24.6 mmol) in anhydrous ether (100 mL) under nitrogen gas was added via syringe MeMgBr (3M solution in ether, 10 mL, 30 mmol) over 3 min. The mixture was poured into a saturated solution of sodium bicarbonate (100 mL), the organic layer was separated and the aqueous layer was extracted with ethyl acetate (100 mL). The combined organic layers were dried over magnesium sulfate, filtered, and concentrated to give a viscous oil. The oil was mixed with acetone (100 mL) and treated with Jones reagent (1.1 M, 40 mL, 1.79 mmol). The mixture was stirred overnight, acetone was evaporated and the residue was extracted with ethyl acetate (60 mL.x.2). The extracts were washed with water (50 mL) and then a saturated aqueous solution of sodium bicarbonate (50 mL). Evaporation gave the ketone as an oil (4.63 g, 87percent) that was used in the next reaction without further purification.
Reference: [1] Patent: US2008/153813, 2008, A1, . Location in patent: Page/Page column 24
[2] Patent: US2007/149548, 2007, A1, . Location in patent: Page/Page column 7
  • 34
  • [ 93777-26-5 ]
  • [ 198477-89-3 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2006, vol. 14, # 20, p. 6832 - 6846
[2] Journal of Medicinal Chemistry, 2012, vol. 55, # 2, p. 935 - 942
[3] Patent: US2013/210839, 2013, A1,
[4] Journal of Medicinal Chemistry, 2017, vol. 60, # 14, p. 6018 - 6035
[5] Patent: WO2007/126964, 2007, A2,
  • 35
  • [ 93777-26-5 ]
  • [ 552331-30-3 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2006, vol. 14, # 20, p. 6832 - 6846
  • 36
  • [ 93777-26-5 ]
  • [ 911305-81-2 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2006, vol. 14, # 20, p. 6832 - 6846
  • 37
  • [ 93777-26-5 ]
  • [ 761423-87-4 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 10, p. 3263 - 3279
[2] Patent: CN108276396, 2018, A,
  • 38
  • [ 93777-26-5 ]
  • [ 627463-25-6 ]
Reference: [1] Patent: WO2018/102751, 2018, A1,
  • 39
  • [ 93777-26-5 ]
  • [ 864770-82-1 ]
Reference: [1] Journal of Medicinal Chemistry, 2017, vol. 60, # 14, p. 6018 - 6035
  • 40
  • [ 93777-26-5 ]
  • [ 872607-89-1 ]
Reference: [1] Patent: WO2011/18454, 2011, A1,
[2] Patent: WO2011/20861, 2011, A1,
  • 41
  • [ 93777-26-5 ]
  • [ 882672-05-1 ]
Reference: [1] Patent: WO2017/46739, 2017, A1,
  • 42
  • [ 93777-26-5 ]
  • [ 881189-58-8 ]
Reference: [1] Patent: WO2014/201073, 2014, A1,
[2] ACS Medicinal Chemistry Letters, 2017, vol. 8, # 1, p. 67 - 72
  • 43
  • [ 93777-26-5 ]
  • [ 951382-34-6 ]
Reference: [1] Patent: CN108276396, 2018, A,
  • 44
  • [ 93777-26-5 ]
  • [ 1034305-17-3 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 10, p. 3263 - 3279
[2] Patent: CN108276396, 2018, A,
  • 45
  • [ 93777-26-5 ]
  • [ 95-15-8 ]
  • [ 1034305-11-7 ]
YieldReaction ConditionsOperation in experiment
89%
Stage #1: With n-butyllithium In tetrahydrofuran at -78℃; for 1.5 h;
Stage #2: at -78℃; for 2 h;
At -78 ° C,16.6 g (124 mmol) of benzothiophene (compound of formula 2) was dissolved in 200 mL of tetrahydrofuran.Add 78.5 mL (937 mmol) of n-butyllithium,The mixture was stirred at -78 ° C for 1.5 hours.Will be 23.95g (118mmol)5-bromo-2-fluorobenzaldehyde (formula 1 compound) is solubleIn 300 mL of tetrahydrofuran,And mixing it with the above benzothiophene solution,Stirring was continued for 2 hours at -78 °C.Water and diethyl ether were added to the reaction mixture.Separating the organic phase,And dried with magnesium sulfate,It is then filtered and dried under vacuum.The obtained crude product was purified by column chromatography (ethyl acetate-hexane).Obtaining benzo[b]thiophene-2-methanol,Α-(5-bromo-2-fluorophenyl) (compound of formula 3) 35.4 g;Purity 99.5percent; yield 89percent;
84.8%
Stage #1: With n-butyllithium In tetrahydrofuran; hexane at -24.2 - -13.5℃; Inert atmosphere
Stage #2: at -23.5 - -11.8℃; Inert atmosphere
Stage #3: With hydrogenchloride; water In tetrahydrofuran; hexane; toluene
EXAMPLE; (Example); First step: Synthesis of 1-benzothien-2-yl(5-bromo-2-fluorophenyl)methanol; Into a tetrahydrofuran (100 liters) solution of benzo[b]thiophene (17.4 kg ) was dropwise added a n-hexane solution (56.2 kg) of n-butyl lithium (15.08percent) in an argon atmosphere at -24.2 to -13.5°C, followed by stirring at -22.1 to -13.5°C for 40 minutes. Into this solution was dropwise added a tetrahydrofuran (18 liters) solution of 5-bromo-2-fluorobenzaldehyde (25.5 kg) at -22.1 to -11.8°C, followed by stirring at -23.5 to -16.1°C for 2 hours. To the reaction mixture were added water (100 liters), toluene (130 liters) and 38percent hydrochloric acid (12.3 kg), and extraction was conducted. The organic layer was washed with water (130 liters) and then subjected to distillation at normal pressure to distill off the solvent until the residue became 100 liters. Toluene (130 liters) was added to the residue and the mixture was subjected to distillation at normal pressure to distil off the solvent until the residue became 100 liters. The operation of adding toluene to the residue and subjecting the mixture to distillation under reduced pressure to distill off the solvent, was repeated twice: Then, n-heptane (310 liters) was added to the residue, followed by heating to dissolve the residue. To the solution was added, as a seed crystal, about 26 g of the 1-benzothien-2-yl(5-bromo-2-fluorophenyl)methanol produced in the same manner as that shown in the first step of Reference Example 1, followed by stirring at 1.2 to 5.0°C for 13 hours. The separated-out crystals were collected by filtration, washed twice with a toluene-n-heptane (1:6) mixed solvent (26 liters), and subjected to vacuum drying to obtain, as white crystals, 1-benzothien-2-yl(5-bromo-2-fluorophenyl)methanol [35.91 kg, yield: 84.8percent, purity: 99percent (HPLC)]. 1H-NMR (CDCl3): δ 2.74 (1H, d), 6.35 (1H, d), 6.93 (1H, dd), 7.14 (1H, s), 7.27-7.38 (2H, m), 7.39 (1H, m), 7.68 (1H, dd), 7.74 (2H, m)
Reference: [1] Patent: CN108276396, 2018, A, . Location in patent: Paragraph 0041; 0046; 0047; 0062; 0077
[2] Patent: EP2105442, 2009, A1, . Location in patent: Page/Page column 13
[3] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 10, p. 3263 - 3279
  • 46
  • [ 141-82-2 ]
  • [ 93777-26-5 ]
  • [ 202865-71-2 ]
YieldReaction ConditionsOperation in experiment
1.3 g at 100℃; for 3 h; 5-Bromo-2-fluoro-benzaldehyde (5.0 g, 24.6 mmol), malonic acid (5.6 g, 53.7 mmol), and piperidine (0.5 mL, 4.9 mmol) were added to pyridine (11.4 mL). The reaction mixture was stirred at 100° C. for 3 hours and then concentrated under reduced pressure. Distilled water was added to the reaction mixture, which was then filtered. The resulting solid was recrystallized from ethanol to give 1.3 g of the titled compound as a white solid. (0164) 1H NMR (400 MHz, CD3OD) 7.89 (d, 1H), 7.74-7.70 (m, 2H), 7.15 (t, 1H), 6.62 (d, 1H)
Reference: [1] Patent: US2015/291563, 2015, A1, . Location in patent: Paragraph 0163; 0164
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 93777-26-5 ]

Ipragliflozin Related Intermediates

Chemical Structure| 95-15-8

[ 95-15-8 ]

Thianaphthene

Chemical Structure| 32384-65-9

[ 32384-65-9 ]

2,3,4,6-Tetra-O-(trimethylsilyl)-D-glucono-delta-lactone

Chemical Structure| 1034305-11-7

[ 1034305-11-7 ]

Benzo[b]thiophen-2-yl(5-bromo-2-fluorophenyl)methanol

Chemical Structure| 13096-62-3

[ 13096-62-3 ]

2,3,4,6-Tetra-O-benzyl-D-glucono-1,5-lactone

Chemical Structure| 1034305-23-1

[ 1034305-23-1 ]

(2S,3R,4S,5S,6R)-2-(3-(Benzo[b]thiophen-2-ylmethyl)-4-fluorophenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol

Related Functional Groups of
[ 93777-26-5 ]

Fluorinated Building Blocks

Chemical Structure| 916792-23-9

[ 916792-23-9 ]

4-Bromo-2-fluoro-5-methylbenzaldehyde

Similarity: 0.96

Chemical Structure| 1807181-56-1

[ 1807181-56-1 ]

4,5-Dibromo-2-fluorobenzaldehyde

Similarity: 0.94

Chemical Structure| 473416-91-0

[ 473416-91-0 ]

5-Bromo-2,4-difluorobenzaldehyde

Similarity: 0.92

Chemical Structure| 633327-22-7

[ 633327-22-7 ]

5-Bromo-2,3-difluorobenzaldehyde

Similarity: 0.92

Chemical Structure| 149947-15-9

[ 149947-15-9 ]

3-Bromo-2-fluorobenzaldehyde

Similarity: 0.92

Aryls

Chemical Structure| 916792-23-9

[ 916792-23-9 ]

4-Bromo-2-fluoro-5-methylbenzaldehyde

Similarity: 0.96

Chemical Structure| 1807181-56-1

[ 1807181-56-1 ]

4,5-Dibromo-2-fluorobenzaldehyde

Similarity: 0.94

Chemical Structure| 473416-91-0

[ 473416-91-0 ]

5-Bromo-2,4-difluorobenzaldehyde

Similarity: 0.92

Chemical Structure| 633327-22-7

[ 633327-22-7 ]

5-Bromo-2,3-difluorobenzaldehyde

Similarity: 0.92

Chemical Structure| 149947-15-9

[ 149947-15-9 ]

3-Bromo-2-fluorobenzaldehyde

Similarity: 0.92

Bromides

Chemical Structure| 916792-23-9

[ 916792-23-9 ]

4-Bromo-2-fluoro-5-methylbenzaldehyde

Similarity: 0.96

Chemical Structure| 1807181-56-1

[ 1807181-56-1 ]

4,5-Dibromo-2-fluorobenzaldehyde

Similarity: 0.94

Chemical Structure| 473416-91-0

[ 473416-91-0 ]

5-Bromo-2,4-difluorobenzaldehyde

Similarity: 0.92

Chemical Structure| 633327-22-7

[ 633327-22-7 ]

5-Bromo-2,3-difluorobenzaldehyde

Similarity: 0.92

Chemical Structure| 149947-15-9

[ 149947-15-9 ]

3-Bromo-2-fluorobenzaldehyde

Similarity: 0.92

Aldehydes

Chemical Structure| 916792-23-9

[ 916792-23-9 ]

4-Bromo-2-fluoro-5-methylbenzaldehyde

Similarity: 0.96

Chemical Structure| 1807181-56-1

[ 1807181-56-1 ]

4,5-Dibromo-2-fluorobenzaldehyde

Similarity: 0.94

Chemical Structure| 473416-91-0

[ 473416-91-0 ]

5-Bromo-2,4-difluorobenzaldehyde

Similarity: 0.92

Chemical Structure| 633327-22-7

[ 633327-22-7 ]

5-Bromo-2,3-difluorobenzaldehyde

Similarity: 0.92

Chemical Structure| 149947-15-9

[ 149947-15-9 ]

3-Bromo-2-fluorobenzaldehyde

Similarity: 0.92